Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2. With the rapid evolution of the pandemic, even the off-label use of existing drugs has been restricted by limited...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_4acb6d9fb57b41f78f4db32d0bee55b9 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Chandan Sarkar |e author |
700 | 1 | 0 | |a Milon Mondal |e author |
700 | 1 | 0 | |a Muhammad Torequl Islam |e author |
700 | 1 | 0 | |a Muhammad Torequl Islam |e author |
700 | 1 | 0 | |a Miquel Martorell |e author |
700 | 1 | 0 | |a Miquel Martorell |e author |
700 | 1 | 0 | |a Anca Oana Docea |e author |
700 | 1 | 0 | |a Alfred Maroyi |e author |
700 | 1 | 0 | |a Javad Sharifi-Rad |e author |
700 | 1 | 0 | |a Daniela Calina |e author |
245 | 0 | 0 | |a Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives |
260 | |b Frontiers Media S.A., |c 2020-09-01T00:00:00Z. | ||
500 | |a 1663-9812 | ||
500 | |a 10.3389/fphar.2020.572870 | ||
520 | |a The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2. With the rapid evolution of the pandemic, even the off-label use of existing drugs has been restricted by limited availability. Several old antivirals, antimalarial, and biological drugs are being reconsidered as possible therapies. The effectiveness of the controversial treatment options for COVID-19 such as nonsteroidal antiinflammatory drugs, angiotensin 2 conversion enzyme inhibitors and selective angiotensin receptor blockers was also discussed. A systemic search in the PubMed, Science Direct, LitCovid, Chinese Clinical Trial Registry, and ClinicalTrials.gov data bases was conducted using the keywords "coronavirus drug therapy," passive immunotherapy for COVID-19', "convalescent plasma therapy," (CPT) "drugs for COVID-19 treatment," "SARS-CoV-2," "COVID-19," "2019-nCoV," "coronavirus immunology," "microbiology," "virology," and individual drug names. Systematic reviews, case presentations and very recent clinical guidelines were included. This narrative review summarizes the available information on possible therapies for COVID-19, providing recent data to health professionals. | ||
546 | |a EN | ||
690 | |a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | ||
690 | |a pandemic | ||
690 | |a COVID-19 proposed therapy | ||
690 | |a convalescent plasma | ||
690 | |a therapeutic challenges | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Pharmacology, Vol 11 (2020) | |
787 | 0 | |n https://www.frontiersin.org/article/10.3389/fphar.2020.572870/full | |
787 | 0 | |n https://doaj.org/toc/1663-9812 | |
856 | 4 | 1 | |u https://doaj.org/article/4acb6d9fb57b41f78f4db32d0bee55b9 |z Connect to this object online. |